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BACKGROUND: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary
treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker,
but this effect is considered to relate to oestrogen receptor (ER) status. This study aimed to test the clinical validity of BCL2 as an
independent prognostic marker.
METHODS: Five studies of 11212 women with early-stage breast cancer were analysed. Individual patient data included tumour size,
grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the
time-dependent effects of each variable was used to explore the prognostic significance of BCL2.
RESULTS: In univariate analysis, ER, PR and BCL2 positivity was associated with improved survival and HER2 positivity with inferior
survival. For ER and PR this effect was time dependent, whereas for BCL2 and HER2 the effect persisted over time. In multivariate
analysis, BCL2 positivity retained independent prognostic significance (hazard ratio (HR) 0.76, 95% confidence interval (CI)
0.66–0.88, Po0.001). BCL2 was a powerful prognostic marker in ER  (HR 0.63, 95% CI 0.54–0.74, Po0.001) and ERþ disease
(HR 0.56, 95% CI 0.48–0.65, Po0.001), and in HER2  (HR 0.55, 95% CI 0.49–0.61, Po0.001) and HER2þ disease (HR 0.70, 95%
CI 0.57–0.85, Po0.001), irrespective of the type of adjuvant therapy received. Addition of BCL2 to the Adjuvant! Online prognostic
model, for a subset of cases with a 10-year follow-up, improved the survival prediction (P¼0.0039).
CONCLUSIONS: BCL2 is an independent indicator of favourable prognosis for all types of early-stage breast cancer. This study
establishes the rationale for introduction of BCL2 immunohistochemistry to improve prognostic stratification. Further work is now
needed to ascertain the exact way to apply BCL2 testing for risk stratification and to standardise BCL2 immunohistochemistry for this
application.
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The management of breast cancer continues to be challenging
because of the heterogeneity of the disease. In early-stage breast
cancer, a limited number of clinical and pathological factors
are currently used to guide prognosis. These factors include age,
tumour size, histological grade, lymphovascular invasion and
oestrogen receptor (ER) status, and have been incorporated into
algorithms such as the Nottingham Prognostic Index or Adjuvant!
Online (AOL) to estimate the individual risk (Haybittle et al, 1982;
Ravdin et al, 2001; Blamey et al, 2007). More recently, amplifica-
tion and/or overexpression of the human epidermal growth factor
receptor 2 (HER2), a therapeutic target, has been associated with
worse prognosis, although its clinical utility as a prognostic marker
remains uncertain (Paik et al, 1990; Yamauchi et al, 2001; Chia
et al, 2008). The variation in clinical outcome despite similar
prognostic scores seriously compromises our ability to advise
women in making informed decisions about adjuvant treatment.
Over several decades, substantial effort has been invested in the
identification and validation of additional prognostic markers to
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simprove risk stratification for breast cancer. Despite this, most
candidate-based prognostic markers, with the exception of
urokinase plasminogen activator and plasminogen activator
inhibitor 1, have not succeeded in making the transition from
the laboratory to clinical practice, as evidenced by the 2007
American Society of Clinical Oncology update on recommenda-
tions for the use of tumour markers for breast cancer (Harris et al,
2007). As the evaluation of candidate prognostic markers is often
limited by inadequate study design and analyses, formal recom-
mendations for reporting tumour marker prognostic studies
(REMARK) have now been agreed upon (McShane et al, 2005).
In recent years, microarray-based technology has resulted in the
identification of breast cancer molecular subtypes (luminal, HER2-
like, basal/triple negative) and gene-expression prognostic signa-
tures (Van‘t Veer et al, 2002; Sorlie et al, 2003; Paik et al, 2006).
These prognostic expression signatures hold great promise,
but there are concerns regarding their significance independent
of ER status and their time dependency (Cardoso et al, 2008;
Sparano and Paik, 2008). The process of validating the clinical
utility of two such expression signatures, Oncotype DX and
Mammaprint, is ongoing through the TAILORx and MINDACT
trials, respectively (Cardoso et al, 2008; Sparano and Paik, 2008).
The results from these large randomised prospective trials will be
unavailable for many years, and the technology is cumbersome,
which may limit its suitability for routine use in clinical practice.
In contrast, immunohistochemistry is well established in routine
diagnostic pathology laboratories.
Analysis of protein expression using immunohistochemistry has
identified molecular subtypes that are similar to those derived
from gene expression arrays (Callagy et al, 2003; Abd El-Rehim
et al, 2005). Our group previously assessed the prognostic value
of combining protein markers used to define these molecular
subtypes. Indeed, we showed that only BCL2 added prognostic
information independent of the Nottingham Prognostic Index and
validated this result (Callagy et al, 2006). Expression of BCL2, an
antiapoptotic protein, is associated with low-grade, slowly
proliferating, ERþ breast tumours (Silvestrini et al, 1994;
Lipponen et al, 1995). Previous studies had identified that
expression of BCL2 was associated with improved survival from
breast cancer, but this was attributed to its correlation with ER
status (Berardo et al, 1998; Charpin et al, 1998; Callagy et al, 2006,
2008; Neri et al, 2006). The aim of the current study was to
prospectively test the clinical validity of BCL2 as a prognostic
marker independent of ER, HER2 and adjuvant therapy received,
in addition to tumour size, grade and nodal status.
METHODS
Study population, tumour samples, immunostaining
and scoring
We have followed the REMARK guidelines for conducting
this tumour marker study (Supplementary Table 1) (McShane
et al, 2005). A total of 11212 early-stage breast cancer cases were
participants in five large studies (all approved by the relevant
institutional review boards or ethics committees): the Study of
Epidemiology and Risk Factors in Cancer Heredity (SEARCH;
n¼3420), the Nottingham Breast Cancer Series (NBCS; n¼1926),
the University of British Columbia Breast Cancer Series (UBCBCS;
n¼976), the British Columbia Cancer Agency Case Series
(BCCA; n¼4040) and the Melbourne Collaborative Cohort Study
(MCCS; n¼850). The criteria for inclusion were the availability of
tumour tissue, pathological data (tumour size, tumour grade,
lymph node status) and individual clinical outcome data (vital
status at last follow-up and date of death). Early-stage breast
cancer was defined as stage I to stage III as per the American Joint
Committee on Cancer (AJCC) (2002). Details of the studies have
been published previously and a summary of the individual studies
is given in Supplementary Table 2 (Ragaz et al, 1997, 2005; Giles
and English, 2002; Abd El-Rehim et al, 2004; Lesueur et al, 2005;
Callagy et al, 2006; Chia et al, 2008). Tissue microarrays were
constructed for the SEARCH, NBCS, UBCBCS and BCCA studies,
as published previously (Kononen et al, 1998; Cheang et al, 2006).
For the MCCS study, whole-tissue sections rather than tissue
microarrays were used. Using these samples, we obtained ER,
progesterone receptor (PR), HER2 and BCL2 data from 8310 cases
(three studies) and pooled it with our previously published data
(two studies) for the same markers from a further 2902 women.
Details of the immunostaining are given in Supplementary
Methods, along with the scoring methods used for ER, PR, HER2
and BCL2 in the different series.
Statistical analysis
Statistical analysis was conducted in concordance with recently
published guidelines for the development of prognostic models in
breast cancer (Altman, 2009). Cox regression analysis stratified by
study was performed to determine the effect of each prognostic
factor and marker on survival after diagnosis. In univariate
analysis, inspection of standard log–log plots showed that the Cox
proportional hazards assumption was clearly violated for all
variables, indicating that the hazard ratio (HR) varied with time
(data not shown). We therefore fitted Cox models in which the HR
was allowed to vary as a function of time (TV) by extending
the basic Cox model to include a time-dependent coefficient in the
linear predictor X. The log HR (HRTV) for any variable (X) at time
(t) is then as follows: log (HRTV)¼(B1þB2 log (t)) X. The Cox
model allowing for time dependence generates two parameter
estimates for each variable (X): B1 (log HR) and B2 (log time effect
(T)). If there is no time dependence, B2 equals zero. If the HR
increases with time, B2 will be positive, and if the HR decreases
with time, B2 will be negative. A comparison of the fit of the time-
dependent models compared with the basic Cox models was
performed using a likelihood ratio test, and the fit of the time-
dependent model was significantly better than the basic model for
all variables. On the basis of model likelihoods, the best-fitting
model for tumour size, grade and nodal status, PR, HER2 and
BCL2 was one with the HR varying as a function of log(time),
whereas for ER, the best-fitting model varied as a linear function of
time, although this was not substantially better than the model
with the HR varying as a function of log(time). Therefore,
log(time) was used in subsequent analyses. The value of adding
BCL2 to the prognostic model was tested using both receiver
operating characteristic (ROC) and relative utility curve analyses
(Pepe et al, 2004; Baker, 2009). Further details of the statistical
analysis are given in Supplementary Methods.
RESULTS
Case and tumour characteristics of 11212 women with
early breast cancer
Baseline clinical and pathology data from the 11212 women are
summarised in Table 1. Differences in recruitment criteria between
each of the five cohorts resulted in some variability in the subject’s
characteristics (Table 1). The UBCBCS series comprised women,
all of whom received adjuvant chemotherapy in the setting of
clinical trials, whereas the other four studies were population-
based cohorts of women with early-stage breast cancer, for whom
adjuvant systemic treatment decisions were taken according to
the standard clinical guidelines at the time. For this reason, a
higher proportion of women in the UBCBCS series had ER ,
node-positive tumours, with higher annual mortality rates. The
mean follow-up of the study population was 8.4 years. In total, 71%
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swere ERþ, 56% were PRþ and 14% were HER2þ. Positive BCL2
expression was identified in 73% of cases (86% of these were ERþ
and 8% were HER2þ). The majority of BCL2þ cases demon-
strated moderate-to-strong BCL2 staining intensity (Figure 1)
and a high percentage of cells stained positively (Supplementary
Figure 1).
Increasing expression levels of BCL2 predict better
survival in early breast cancer
The impact of differential BCL2 expression was explored by
comparing the HR for women with tumours showing varying levels
of BCL2 staining intensity using a simple univariate analysis
(Figure 1A). A direct relationship between the intensity of BCL2
staining and survival was identified (Figure 1B). Women whose
tumours demonstrated the most intense BCL2 staining had the
best survival.
BCL2 is a time-independent good prognostic marker in
early breast cancer
Univariate analysis using the Cox model allowing for time
dependence indicated that the HRs for all variables showed
time-dependent effects (Table 2). In an initial multivariate model,
which included ER, PR, HER2 and BCL2 (Table 2; model 1), a time-
dependent relationship was identified for ER and PR, but not for
BCL2 or HER2. In particular, for ER status, a significant increase in
HR was noted over time. ER positivity was associated with a
favourable prognostic effect for the first 4 years of follow-up
(i.e., HRo1.0), but thereafter, ER positivity was associated with an
adverse outcome and increased risk of death (i.e., HR41.0)
(Supplementary Figure 2A). In contrast, BCL2 positivity continued
to be associated with a favourable prognostic effect throughout the
follow-up period.
The time-dependent effects on HRs can be explained by the fact
that the mortality rate in ER  disease peaks in the initial 2 years
after diagnosis, followed by a steady decline over time (Supple-
mentary Figure 2B). In contrast, although the peak mortality rate
for those with ERþ disease is considerably lower in the first few
years after diagnosis, there is little change in this mortality rate
over time. Eventually, with long-term follow-up, the mortality
rate for ER  disease falls below the mortality rate for ERþ disease
(Supplementary Figure 2B). A similar trend is noted in the
mortality rate for those with BCL2  vs BCL2þ disease, but
the variation is not as marked and the mortality rate for BCL2þ
disease continues to be lower than that for BCL2  disease over
time (Supplementary Figure 2B). Therefore, unlike ER positivity,
BCL2 positivity retains its favourable prognostic effect with long-
term follow-up.
BCL2 is a prognostic marker independent of
clinical–pathological characteristics, molecular subtypes
and adjuvant therapy
In a final multivariate model containing tumour size, grade,
nodal status, ER, PR, HER2 and BCL2 status, a time-dependent
Table 1 Characteristics of cases by study
SEARCH NBCS UBCBCS MCCS BCCA Total
No. of patients 3420 1926 976 850 4040 11212
Mean age (years, range) 52 (23–69) 54 (18–70) 48 (22–90) 60 (41–79) 59 (23–95) 55 (18–95)
Mean follow-up (years, range) 7.3 (0.5–15.9) 5.2 (0–12.6) 9.7 (0–39.4) 7.2 (0–16.2) 10.9 (0–18.5) 8.4 (0–39.4)
Number of deaths (%) 469 (14) 416 (22) 492 (50) 133 (16) 1136 (28) 2646 (24)
Annual mortality (%) 2.3 4.2 5.8 1.7 2.7 3.0
Tumour size (n (%))
o2cm 1272 (57) 1023 (53) 114 (12) 543 (66) 1594 (40) 5133 (52)
2–4.9cm 872 (39) 853 (44) 569 (62) 262 (32) 2108 (53) 4092 (42)
X5cm 93 (4) 42 (2) 238 (26) 23 (3) 301 (8) 568 (6)
Grade (n (%))
1 624 (22) 363 (19) 68 (9) 171 (22) 211 (5) 1436 (14)
2 1350 (47) 645 (34) 234 (32) 348 (44) 1578 (41) 4108 (41)
3 884 (31) 907 (47) 425 (59) 265 (34) 2067 (54) 4522 (45)
Nodal status (n (%))
Negative 1346 (62) 1218 (64) 238 (30) 521 (66) 2156 (55) 5397 (57)
Positive 834 (38) 695 (36) 562 (70) 228 (30) 1741 (45) 4031 (43)
ER status (n (%))
Negative 657 (20) 536 (30) 491 (55) 129 (28) 1224 (31) 3050 (29)
Positive 2681 (80) 1253 (70) 409 (45) 333 (72) 2785 (69) 7542 (71)
PR status (n (%))
Negative 708 (30) 772 (44) 503 (60) 222 (48) 1758 (49) 3692 (44)
Positive 1621 (70) 993 (56) 338 (40) 237 (51) 1843 (51) 5110 (56)
HER2 status (n (%))
Negative 1329 (89) 1341 (92) 637 (71) 407 (88) 3355 (87) 7006 (86)
Positive 172 (11) 116 (8) 256 (29) 54 (12) 506 (13) 1094 (14)
BCL2 status (n (%))
Negative 488 (24) 270 (27) 258 (35) 198 (43) 971 (26) 2132 (27)
Positive 1509 (76) 714 (73) 471 (65) 265 (57) 2743 (74) 5671 (73)
Abbreviations: BCCA¼British Columbia Cancer Agency Case Series; BCL2¼B-cell lymphoma 2; ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2;
MCCS¼Melbourne Collaborative Cohort Study; NBCS¼Nottingham Breast Cancer Series; PR¼progesterone receptor; SEARCH¼Study of Epidemiology and Risk Factors in
Cancer Heredity; UBCBCS¼University of British Columbia Breast Cancer Series.
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srelationship was confirmed for all variables except tumour size,
HER2 and BCL2. The most pertinent model was therefore one that
included the main effect for tumour size, grade, nodal status, ER,
PR, HER2 and BCL2, in addition to time-dependent effects for all
variables except tumour size, HER2 and BCL2 (Table 2; model 2).
In this model, BCL2 remained an independent predictor of survival
(BCL2þ vs BCL2 ; HR 0.76, 95% confidence interval (CI)
0.66–0.88, P¼0.0002).
BCL2 was found to be prognostic in each of the five studies
analysed (Figure 2). Furthermore, given that the prognostic impact
of BCL2 had initially been determined in the UBCBCS series
(previously published data) (Callagy et al, 2006), the current model
was assessed in the remaining four studies to independently
validate the original findings (BCL2þ vs BCL2 ; HR 0.79, 95% CI
0.68–0.93, P¼0.003) (Supplementary Table 3).
The prognostic impact of BCL2 positivity remained regardless of
other tumour characteristics, including tumour size, grade and
lymph node status (Figure 2). BCL2 was a prognostic factor in
women with both ER  (HR 0.63, 95% CI 0.54–0.74, Po0.001) and
ERþ disease (HR 0.56, 95% CI 0.48–0.65, Po0.001) (Figures 2
and 3B). It is of importance that women with ERþ/BCL2  disease
were found to have a worse prognosis than those with
ER /BCL2þ disease (HR 1.35, 95% CI 1.10–1.65, P¼0.004).
BCL2 was also a strong prognostic marker in women with both
HER2  (HR 0.55, 95% CI 0.49–0.61, Po0.001) and HER2þ disease
(HR 0.70, 95% CI 0.57–0.85, Po0.001) (Figures 2 and 3C) and
women with triple-negative disease (i.e., ER ,P R   and HER2 )
(HR 0.67, 95% CI 0.54–0.84, Po0.001) (Figures 2 and 3D).
Finally, the prognostic impact of BCL2 remained irrespective of
whether women had received adjuvant chemotherapy (HR 0.58,
95% CI 0.51–0.67, Po0.001) (Figures 2 and 3E) or adjuvant
endocrine therapy (HR 0.56, 95% CI 0.44–0.70, Po0.001) (Figures
2 and 3F).
BCL2 inclusion as a prognostic marker improves survival
prediction
To further assess the final prognostic model (model 2), we used
grade, stage, nodal status, ER, PR and BCL2, in addition to time-
dependent effects for all variables except nodal status and BCL2,
to predict the expected number of deaths across all five studies.
The area under the ROC curve was assessed to compare the
performance of the predictive model with and without
the inclusion of BCL2 (Pepe et al, 2004). An improvement in the
prediction of the model was observed with the addition of BCL2
(area under ROC 0.6844 with BCL2 vs 0.6774 without BCL2,
P¼0.012).
Furthermore, the addition of BCL2 to the risk prediction
provided by AOL was assessed in the BCCA series, for which we
had 10-year follow-up data. The area under the ROC curve was
significantly improved when BCL2 was added to the AOL risk
prediction algorithm compared with the use of AOL alone (area
under ROC 0.7224 for BCL2 and AOL vs 0.7137 for AOL,
P¼0.0039). The improved performance of the AOL risk prediction
algorithm with the addition of BCL2 was also confirmed using a
relative utility curve (Figure 4) (Baker, 2009). The relative utility is
the fraction of the expected utility of perfect prediction achieved at
the optimal cutoff point for a risk prediction model. Of particular
note is that the relative utility of AOL and BCL2 was superior to the
performance of AOL alone at lower risk thresholds at which
clinical decision making regarding the use of adjuvant chemo-
therapy is more difficult.
DISCUSSION
A great challenge in breast cancer management is to identify
patients who will not benefit from systemic adjuvant chemother-
apy. Current approaches are hindered by a dearth of clinically
useful biomarkers, with the exception of ER and possibly
HER2/neu. Although promising, the readiness of gene expression
signatures to further stratify patients awaits the results of
prospective studies. In contrast, immunohistochemical analysis
of BCL2 protein expression is a simple, well-validated, inexpensive
and widely available test (used routinely in diagnostic pathology of
low-grade lymphoproliferative disorders). The prospective analysis
in over 11000 women with early-stage breast cancer reported
here demonstrates for the first time the robust prognostic
significance of BCL2 protein expression independent of ER, as
well as all the other traditional prognostic markers used in clinical
practice (see Figure 2) (Hayes et al, 1996).
Significant temporal variation exists in the relative contribution
of individual prognostic markers during prolonged follow-up,
further limiting their clinical value. Our analysis confirms the
previously described time dependence of hormone receptors (ER
and PR) as prognostic markers in breast cancer (Hilsenbeck et al,
1998; Anderson et al, 2006). This time dependence has also been
noted in gene expression signatures that appear to be better
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Figure 1 Prognostic significance of BCL2 according to the level of BCL2
expression. (A) Immunohistochemical evaluation of BCL2 staining intensity.
Immunohistochemical analysis of BCL2 from the SEARCH series (BCL2
antibody, Dako clone 124, 1:200). (B) Kaplan–Meier curve of cumulative
survival according to BCL2 staining intensity. 0¼no BCL2 staining:
n¼1646, HR¼1.00; 1¼weak BCL2 staining intensity: n¼1100,
HR¼0.76, 95% CI 0.66–0.88, Po0.001; 2¼moderate BCL2 staining
intensity: n¼1921, HR¼0.55, 95% CI 0.49–0.63, Po0.001; 3¼strong
BCL2 staining intensity: n¼3022, HR¼0.45, 95% CI 0.40–0.51, Po0.001.
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spredictors of relapse in the first 5 years (Desmedt et al, 2007;
Cardoso et al, 2008). In contrast, our study reveals that the
prognostic effect of BCL2 protein expression is time independent
and BCL2 continues to be associated with favourable outcome over
time, increasing its potential clinical value given the frequent
occurrence of late relapses (particularly in ERþ breast cancer).
BCL2 belongs to a group of related proteins that are key
regulators of apoptosis or programmed cell death (Cory et al,
2003). The tumourigenic potential of inappropriate BCL2 protein
expression was first described as a result of the chromosomal
translocation (t(14,18)) seen in subsets of non-Hodgkin’s lympho-
ma, in which it is associated with adverse outcome (Tsujimoto
et al, 1984). Since this discovery, overexpression of BCL2 protein
has been identified in a variety of solid organ malignancies,
including breast cancer. In contrast to non-Hodgkin’s lymphoma,
BCL2 protein expression in breast cancer is associated with an
indolent phenotype of low-grade, slowly proliferating, ERþ breast
tumours (Silvestrini et al, 1994; Lipponen et al, 1995). This
‘paradoxical’ favourable prognostic effect of BCL2 in breast cancer
could be related to its non-apoptotic functions (Pietenpol et al,
1994; O’Reilly et al, 1996). Increased expression of BCL2 protein
may also disrupt the balance with other members of the BCL2
family, including the expression of pro-apoptotic proteins (Cory
et al, 2003).
The exact mechanism of differential BCL2 protein expression in
breast cancer is complex. BCL2 is expressed in normal breast
glandular epithelium and is known to be upregulated by oestrogen,
possibly as a direct result of transcriptional induction (Wang and
Phang, 1995; Leung and Wang, 1999). We show that, in cancers,
BCL2 positivity is not simply a surrogate for ER positivity: 14%
of BCL2þ tumours were ER  and 31% of BCL2  tumours were
ERþ. BCL2 amplification/copy number gain is rare and correla-
tion between transcript and protein levels in breast cancer is not
linear (unpublished observations), suggesting post-transcriptional
regulation. Therefore, although in Oncotype DX (Paik et al, 2004),
BCL2 is one of the 21 genes in the prognostic signature,
measurement of BCL2 protein expression may provide prognostic
information that is not identical.
The prognostic value of BCL2 was present across molecular
subtypes (ERþ/luminal, HER2þ, HER2  and triple negative), an
Table 2 Cox model incorporating time-dependent effects of prognostic variables
HR B1 95% CI P-value TB 2 95% CI P-value
Univariate analysis
Size (n¼9793) 2.74 1.01 2.39–3.14 o0.001 0.79  0.24 0.72–0.86 o0.001
Grade (n¼10066) 5.30 1.67 4.40–6.40 o0.001 0.53  0.63 0.47–0.59 o0.001
Nodal status (n¼9428) 4.02 1.39 3.30–4.90 o0.001 0.76  0.27 0.67–0.87 o0.001
ER (n¼10592) 0.17  1.77 0.14–0.20 o0.001 2.49 0.91 2.24–2.76 o0.001
PR (n¼8802) 0.15  1.90 0.13–0.19 o0.001 2.45 0.90 2.19–2.75 o0.001
HER2 (n¼8100) 2.85 1.05 2.34–3.48 o0.001 0.70  0.36 0.61–0.80 o0.001
BCL2 (n¼7803) 0.21  1.56 0.17–0.25 o0.001 2.02 0.70 1.78–2.31 o0.001
Multivariate analysis: Model 1 (n¼6738)
ER 0.39  0.94 0.29–0.51 o0.001 1.99 0.69 1.65–2.41 o0.001
PR 0.30  1.20 0.23–0.40 o0.001 1.76 0.57 1.49–2.08 o0.001
HER2 1.50 0.41 1.20–1.89 o0.001 0.97  0.03 0.82–1.14 0.69
BCL2 0.62  0.48 0.48–0.80 o0.001 1.09 0.09 0.92–1.29 0.32
Multivariate analysis: Model 2 (n¼5445)
Size 1.50 0.41 1.37–1.64 o0.001 NA
Grade 2.89 1.06 2.18–3.80 o0.001 0.67  0.40 0.57–0.79 o0.001
Nodal status 3.21 1.17 2.50–4.12 o0.001 0.80  0.22 0.68–0.94 0.006
ER 0.41  0.89 0.30–0.54 o0.001 2.07 0.73 1.70–2.50 o0.001
PR 0.33  1.11 0.24–0.46 o0.001 1.69 0.52 1.41–2.03 o0.001
HER2 1.31 0.27 1.15–1.50 o0.001 NA
BCL2 0.76  0.25 0.66–0.88 o0.001 NA
Abbreviations: B1¼log(hazard ratio); B2¼log(time effect); BCL2¼B-cell lymphoma 2; CI¼confidence interval; ER¼oestrogen receptor; HER2¼human epidermal growth
factor receptor 2; HR¼hazard ratio (mortality); NA¼not applicable; PR¼progesterone receptor; T¼time effect. B2 is positive when the HR increases with time and negative
when the HR decreases with time. Tumour size and grade were treated as continuous variables in the univariate and multivariate analyses.
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Figure 2 Prognostic significance of BCL2 according to study, tumour
characteristics and type of adjuvant therapy. Plot showing the hazard ratio
and 95% confidence intervals for BCL2 positivity according to the individual
study, tumour characteristics (ER, HER2, TNP (triple-negative phenotype),
tumour grade, lymph node status, tumour size) and the type of adjuvant
therapy received.
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simportant new observation, and was independent of tumour size,
grade and stage. Women with ERþ/BCL2  disease were found
to have a worse prognosis than those with ER /BCL2þ disease.
The interaction between treatment and the prognostic role of BCL2
was also addressed, showing that the prognostic impact of BCL2 is
independent of adjuvant therapy received. Finally, BCL2 is an
important prognostic variable in a risk prediction setting and
improves the performance of prediction algorithms such as AOL.
Novel markers that could be used to save women from
unnecessary cytotoxic adjuvant therapy are urgently needed and
BCL2 provides valuable additional prognostic information to guide
clinical decision making in this setting.
In summary, this large analysis establishes BCL2 as an
independent and powerful prognostic protein marker in early-
stage breast cancer. BCL2 provides prognostic information in
all subgroups defined by other prognostic factors. Thus, it
could be used with prediction algorithms such as AOL
to improve the ability to discriminate risk groups, by simply
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Figure 3 Prognostic significance of BCL2 according to hormonal status, HER2 status and adjuvant therapy. Kaplan–Meier curves of cumulative survival
according to (A) BCL2 status: (i) BCL2 ,H R ¼1.00; (ii) BCL2þ,H R ¼0.76, 95% CI 0.66–0.88, Po0.001. (B) Oestrogen receptor and BCL2 status:
(i) ER /BCL2 ,H R¼1.00; (ii) ERþ/BCL2 ,H R¼0.81, 95% CI 0.69–0.96, P¼0.012; (iii) ER /BCL2þ,H R¼0.62, 95% CI 0.53–0.71, Po0.001; (iv) ERþ/
BCL2þ,H R ¼0.46, 95% CI 0.42–0.51, Po0.001. (C) Human epidermal growth factor receptor 2 and BCL2 status: (i) HER2 /BCL2 ,H R ¼1.00;
(ii) HER2þ/BCL2 ,H R ¼1.36, 95% CI 1.17–1.59, Po0.001; (iii) HER2 /BCL2þ,H R ¼0.55, 95% CI 0.49–0.61, Po0.001; (iv) HER2þ/BCL2þ;
n¼399, HR¼0.94, 95% CI 0.78–1.13, P¼0.52. (D) Triple-negative phenotype (TNP) and BCL2 status: (i) non-TNP/BCL2 ,H R¼1.00; (ii) TNP/BCL2 ,
HR¼1.43, 95% CI 1.18–1.74, Po0.001; (iii) non-TNP/BCL2þ,H R¼0.56, 95% CI 0.49–0.65, Po0.001; (iv) TNP/BCL2þ,H R¼1.19, 95% CI 0.83–1.73,
P¼0.34. (E) Adjuvant chemotherapy and BCL2 status: (i) adjuvant chemotherapy/BCL2 ,H R ¼1.00; (ii) adjuvant chemotherapy/BCL2þ,H R ¼0.76,
95% CI 0.71–0.82, Po0.001. (F) Adjuvant endocrine therapy and BCL2 status: (i) adjuvant endocrine therapy/BCL2 ,H R¼1.00; (ii) adjuvant endocrine
therapy/BCL2þ,H R¼0.69, 95% CI 0.64–0.75, Po0.001.
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susing the HRs and the prevalence of BCL2 positivity in each
subgroup we report. Indeed, the assignment of patients to risk
groups is significantly altered by BCL2 expression (see Figures
2–4). The exact way to apply BCL2 testing for risk stratification
and the approach to standardise BCL2 immunohistochemistry for
this application will now require rigorous prospective assessment,
but, given our findings reported here, this is feasible.
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